Literature DB >> 10843702

Delta 9-tetrahydrocannabinol treatment suppresses immunity and early IFN-gamma, IL-12, and IL-12 receptor beta 2 responses to Legionella pneumophila infection.

T W Klein1, C A Newton, N Nakachi, H Friedman.   

Abstract

The marijuana cannabinoid, delta 9-tetrahydrocannabinol (THC), suppresses immunity to Legionella pneumophila and development of Th1 activity and cell-mediated immunity. In the current study, THC effects on cytokines regulating the development of Th1 cells were examined. BALB/c mice showed significant increases in serum IL-12 and IFN-gamma within hours of infection; however, the levels of these Th1-promoting cytokines as well as resistance to a challenge infection were suppressed by THC (8 mg/kg) injected 18 h before priming. The Th2-promoting cytokine, IL-4, was increased within hours of a Legionella infection and was further increased by THC treatment. These results suggested that THC injection suppressed the cytokine environment promoting Th1 immunity. In additional experiments, THC pretreatment and infection of IL-4 knockout mice showed that serum IL-12 and IFN-gamma were suppressed equally in both knockout and normal mice. This suggested that the drug-induced increase in IL-4 was not responsible for the decreases in serum IL-12 and IFN-gamma. However, THC treatment was shown to suppress the expression of IL-12 receptor beta 2 mRNA, indicating that, in addition to suppression of IL-12, THC injection suppressed the expression of IL-12 receptors. Finally, the role of cannabinoid receptors in Th1-promoting cytokine suppression was examined, and results with receptor antagonists showed that both cannabinoid receptors 1 and 2 were involved. It is suggested that suppression of Th1 immunity to Legionella is not due to an increase in IL-4 production but to a decrease in IFN-gamma and IL-12. Furthermore, both types of cannabinoid receptors are involved.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10843702     DOI: 10.4049/jimmunol.164.12.6461

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  53 in total

Review 1.  Microbial infections, immunomodulation, and drugs of abuse.

Authors:  Herman Friedman; Catherine Newton; Thomas W Klein
Journal:  Clin Microbiol Rev       Date:  2003-04       Impact factor: 26.132

2.  Perinatal exposure to Δ9-tetrahydrocannabinol triggers profound defects in T cell differentiation and function in fetal and postnatal stages of life, including decreased responsiveness to HIV antigens.

Authors:  Catherine Lombard; Venkatesh L Hegde; Mitzi Nagarkatti; Prakash S Nagarkatti
Journal:  J Pharmacol Exp Ther       Date:  2011-08-10       Impact factor: 4.030

3.  Exposure of Adolescent Mice to Delta-9-Tetrahydrocannabinol Induces Long-Lasting Modulation of Pro- and Anti-Inflammatory Cytokines in Hypothalamus and Hippocampus Similar to that Observed for Peripheral Macrophages.

Authors:  Sarah Moretti; Silvia Franchi; Mara Castelli; Giada Amodeo; Lorenzo Somaini; Alberto Panerai; Paola Sacerdote
Journal:  J Neuroimmune Pharmacol       Date:  2015-02-10       Impact factor: 4.147

Review 4.  Effects of Cannabinoids on T-cell Function and Resistance to Infection.

Authors:  Toby K Eisenstein; Joseph J Meissler
Journal:  J Neuroimmune Pharmacol       Date:  2015-04-16       Impact factor: 4.147

Review 5.  Drugs of abuse, immune modulation, and AIDS.

Authors:  Guy A Cabral
Journal:  J Neuroimmune Pharmacol       Date:  2006-06-28       Impact factor: 4.147

6.  Recreational drug use and risk of Kaposi's sarcoma in HIV- and HHV-8-coinfected homosexual men.

Authors:  Chun Chao; Lisa P Jacobson; Frank J Jenkins; Donald Tashkin; Otoniel Martínez-Maza; Michael D Roth; Leslie Ng; Joseph B Margolick; Joan S Chmiel; Zuo-Feng Zhang; Roger Detels
Journal:  AIDS Res Hum Retroviruses       Date:  2009-02       Impact factor: 2.205

Review 7.  Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation.

Authors:  Guy A Cabral; LaToya Griffin-Thomas
Journal:  Expert Rev Mol Med       Date:  2009-01-20       Impact factor: 5.600

8.  Modulation of HIVGP120 Antigen-Specific Immune Responses In Vivo by Δ9-Tetrahydrocannabinol.

Authors:  Weimin Chen; Robert B Crawford; Barbara L F Kaplan; Norbert E Kaminski
Journal:  J Neuroimmune Pharmacol       Date:  2015-04-22       Impact factor: 4.147

9.  Modulation of gut-specific mechanisms by chronic δ(9)-tetrahydrocannabinol administration in male rhesus macaques infected with simian immunodeficiency virus: a systems biology analysis.

Authors:  Patricia E Molina; Angela M Amedee; Nicole J LeCapitaine; Jovanny Zabaleta; Mahesh Mohan; Peter J Winsauer; Curtis Vande Stouwe; Robin R McGoey; Matthew W Auten; Lynn LaMotte; Lawrance C Chandra; Leslie L Birke
Journal:  AIDS Res Hum Retroviruses       Date:  2014-02-07       Impact factor: 2.205

10.  Attenuation of experimental autoimmune hepatitis by exogenous and endogenous cannabinoids: involvement of regulatory T cells.

Authors:  Venkatesh L Hegde; Shweta Hegde; Benjamin F Cravatt; Lorne J Hofseth; Mitzi Nagarkatti; Prakash S Nagarkatti
Journal:  Mol Pharmacol       Date:  2008-04-03       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.